Parkinsons Institute

Sunnyvale, CA, United States

Parkinsons Institute

Sunnyvale, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Parkinsons Institute and Stanford University | Date: 2016-08-31

Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.


Goldman S.M.,Parkinsons Institute
Annual Review of Pharmacology and Toxicology | Year: 2014

Parkinson's disease (PD) is a chronic, progressive, disabling neurodegenerative disorder that begins in mid to late life and is characterized by motor impairment, autonomic dysfunction, and, in many, psychological and cognitive changes. Recent advances have helped delineate pathogenetic mechanisms, yet the cause of PD in most individuals is unknown. Although at least 15 genes and genetic loci have been associated with PD, identified genetic causes are responsible for only a few percent of cases. Epidemiologic studies have found increased risk of PD associated with exposure to environmental toxicants such as pesticides, solvents, metals, and other pollutants, and many of these compounds recapitulate PD pathology in animal models. This review summarizes the environmental toxicology of PD, highlighting the consistency of observations across cellular, animal, and human studies of PD pathogenesis. © 2014 by Annual Reviews.


Patent
Neuraltus Pharmaceuticals, Parkinsons Institute and The Hospital For Sick Children | Date: 2014-06-16

Compositions and methods are provided for treating a disorder characterized by -synuclein dysfunction and/or altered lipid metabolism.


Patent
Parkinsons Institute | Date: 2016-07-11

Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinsons Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.


The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.


Patent
Stanford University and Parkinsons Institute | Date: 2013-12-06

Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.


The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.


The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.


Patent
Parkinsons Institute | Date: 2015-09-29

Disclosed are novel phosphorylation sites identified in LRRK2 and associated with Parkinsons Disease, antibodies that specifically bind to the novel phosphorylation sites, and laboratory and clinical uses thereof.


The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

Loading Parkinsons Institute collaborators
Loading Parkinsons Institute collaborators